Global Search

Hide Filters

Showing 2951 results

Event / Oct 27, 2025

Novartis agrees to acquire Avidity Biosciences
Event / Oct 30, 2025

Novartis Immunology Portfolio Update
Event / Nov 20, 2025

Meet Novartis Management 2025
Event / Dec 01, 2025

Annual Social Impact & Sustainability investor event 2025
Animal Research
Ad hoc release / Feb 04, 2026

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from…
Ad hoc release / Feb 04, 2026

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline

Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf…
Ad hoc release / Nov 20, 2025

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for…
Novartis financial data
Expected currency impact